medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 2

<< Back Next >>

Ann Hepatol 2005; 4 (2)

Prediction of the hepatitis C viremia using immunoassay data and clinical expertise

Chiquete E, Sánchez LV, Maldonado M, Quezada D, Panduro A

Language: English
References: 29
Page: 107-114
PDF size: 82.54 Kb.


Text Extraction

Detection of anti-hepatitis C virus (anti-HCV) antibodies may yield a high frequency of false-positive results in people at low risk. To date, no clinical rule had been developed to predict viremia in HCV-seropositive patients. Therefore, we aimed to generate a prediction rule on the basis of clinical and serologic data, which can be used in outpatient care. We selected 114 seropositive patients without antiviral treatment or hepatitis B coinfection. Subsequently we identified independent predictors of the hepatitis C viremia by logistic regression and selected the quantitative value of the screening test for anti-HCV antibodies with the best performance in detecting viremia. Then, we combined clinical and serologic data to generate different prediction rules. Ratio of immunoassay signal strength of the sample to cut-off (S/CO) ›15 had accuracy, positive predictive value (PPV) and positive likelihood ratio (LR+) of 84%, 83%, and 3.7; respectively. The rule compounded of the antecedent of blood transfusion before 1993 and S/CO ›15 performed the best in prediction of viremia in all patients, with accuracy, PPV and LR+ of 71%, 88%, and 5.6; respectively. In the group of asymptomatic patients this rule improved in efficacy of prediction, with accuracy, PPV and LR+ of 79%, 91% and 12.8; respectively. In conclusion, a clinical rule is better than S/CO alone in prediction of the hepatitis C viremia. In a patient that meet the rule the probability of having viremia is high, therefore, it can be indicated directly an assay for viral load instead of other supplemental tests, thus, saving time and economic resources.


REFERENCES

  1. Memom MI, Memom MA. Hepatitis C: an epidemiological review. J Viral Hepat 2002; 9: 84-100.

  2. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, et al. Routs of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.

  3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-3000.

  4. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB (eds). Diagnosis and screening. In: Evidence-based medicine: How to teach and practice EBM. 2nd ed. Edinburgh: Churchill-Livingstone; 2000: 67-93.

  5. Alter MJ, Kuhnert WL, Finelli L; Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003 Feb 7; 52 (RR-3): 1-13.

  6. Dal Molin G, Tiribelli C, Campello C. A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. Ann Hepatol 2003; 2: 76-83.

  7. McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result? Lancet 1990; 335: 754-757.

  8. Aceti A, Taliani G, Bac C, Sebastiani A. Anti-HCV false positivity in malaria. Lancet 1990; 336: 1442-1443.

  9. Schirm J, van Loon AM, Valentine-Thon E, Klapper PE, Reid J, Cleator GM. External quality assessment program for qualitative and quantitative detection of hepatitis C virus RNA in diagnostic virology. J Clin Microbiol 2002; 40: 2973-2980.

  10. Sánchez LV, Maldonado M, Bastidas-Ramírez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol 2002; 68: 22-34.

  11. Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 2004; 44: 349-358.

  12. Rivas-Estilla AM, Sánchez LV, Matsui O, Campollo O, Armendáriz-Borunda Juan, Segura-Ortega JE, Panduro A, et al. Identification of hepatitis C virus (HCV) genotypes in infected patients from the west of Mexico. Hepatology Research 1998; 12: 121-130.

  13. Navas S, Castillo I, Carreńo V. Detection of plus and minus HCV RNA in normal liver of anti-HCV-positive patients. Lancet 1993; 341: 904-905.

  14. Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, Simpson KJ, Hayes PC. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998; 42: 570-575.

  15. Dries V, von Roth I, Müller M, Gerken G, Schirmacher P, Odenthal M, Bartenschlager R, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology 1999; 29: 223-229.

  16. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, Salas C, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.

  17. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1691.

  18. Sookoian S, Castańo G. Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 2002; 4: 179-178.

  19. Dufour DR, Talastas M, Fernandez MDA, Harris B. Chemiluminescence assay improves specificity of hepatitis C antibody detection. Clin Chem 2003; 49: 940-944.

  20. Bossi V, Galli C. Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clin Virol 2004; 30: 45-49.

  21. Polywka S, Schröter M, Feucht HH, Zöllner B, Laufs R. Relevance in reactivity in commercially available hepatitis C virus antibody assay. J Clin Microbiol 2001; 39: 1665-1668.

  22. Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, et al. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J Viral Hepat 2004; 11: 563-570.

  23. Marín-López A. Bancos de Sangre. Rev Gastroenterol Mex 2002; 67: S11-S12.

  24. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-33.

  25. CONADICT. Statistics on drug abuse patterns, Mexico. 2001. Available at http://www.conadic.gob.mx/ Accessed August 24, 2004.

  26. Vivas-Arceo C, Benavides SA, De Jesus Trujillo J, Panduro A, Rivas-Estilla AM. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res 2003; 25: 115-123.

  27. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection. Host, viral, and environmental factors. JAMA 2000; 284: 450-456.

  28. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, Crivellaro C, et al. Chronic hepatitis C virus infection in childhood: Clinical Patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275-280.

  29. Casiraghi MA, De Paschale M, Romano L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39: 90-96.




2020     |     www.medigraphic.com